Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692964 · ClinicalTrials.gov registry record
Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye
A clinical trial of Dysfunctional Tear Syndrome, sponsored by Rapid Pathogen Screening.
- Completed
- Registry status
- 237
- Enrollment target
- 4
- Study locations
NCT01692964 is a study of Dysfunctional Tear Syndrome that has completed, run by Rapid Pathogen Screening. The registered enrollment target is 237 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT01692964, a study of Dysfunctional Tear Syndrome, has completed, sponsored by Rapid Pathogen Screening.
- COMPLETED
- Registry status
- 237 participants
- Enrollment target
- 4
- Study locations
Study Summary
InflammaDry is a rapid diagnostic test for the detection of elevated levels of Matrix Metalloproteinase-9 (MMP-9) protein in tear fluid.
Conditions Studied
Interventions
- DEVICE InflammaDry
Study Locations (4)
Florida
- Manatee-Sarasota Eye Clinic - Bradenton
Missouri
- Mercy Clinic - Eye Specialists - Springfield
New York
- Ophthalmic Associates - Johnson City
Texas
- Ophthalmology Diagnostics & Clinical Research - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692964
The ClinicalTrials.gov registry entry for NCT01692964 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapid Pathogen Screening, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dysfunctional Tear Syndrome appearing as the primary indexed condition, and to 1 intervention - of which InflammaDry is the first listed.
NCT01692964 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT01692964 about?
NCT01692964 is a clinical study titled "Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye". InflammaDry is a rapid diagnostic test for the detection of elevated levels of Matrix Metalloproteinase-9 (MMP-9) protein in tear fluid.
What is the current status of trial NCT01692964?
This trial is currently completed. The enrollment target is 237 participants. The study started on 2012-10. Estimated completion is 2013-05.
What conditions does trial NCT01692964 study?
This clinical trial studies the following conditions: Dysfunctional Tear Syndrome.
What interventions are being tested in trial NCT01692964?
The interventions under investigation include: InflammaDry (DEVICE).
Who is sponsoring clinical trial NCT01692964?
This trial is sponsored by Rapid Pathogen Screening, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01692964 being conducted?
This trial has 4 study locations across Florida, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.